Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Multi-drug resistance (MDR) (2)
- Thomas jefferson university (2)
- Assessment (1)
- Breast Cancer (1)
- Breast Neoplasms (1)
-
- Breast cancer (1)
- CBCT (1)
- Cancer (1)
- Drug delivery (1)
- Elekta Linac (1)
- Energy delivery (1)
- Epidermal growth factor receptor (EGFR) (1)
- Lonidamine (1)
- Lymph Node (1)
- MLC Quality Assurance (1)
- Multi-functional nanocarriers (1)
- Optical Guidance System (1)
- Paclitaxel (1)
- Pathology (1)
- Patient Setup (1)
- Phantom (1)
- Polymer blend nanocarriers (1)
- Procedure (1)
- Resistance modulators (1)
- Standardizing (1)
- Publication
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Optical Guidance System Vs. Cbct For Phantom And Patient Setup, L. Fu, H. Perera, H. Liu, Y. Xiao, Y. Yu
Optical Guidance System Vs. Cbct For Phantom And Patient Setup, L. Fu, H. Perera, H. Liu, Y. Xiao, Y. Yu
Hua Kun Liu
Purpose: To quantify the discrepancy between Varian optical guidance (OG) frameless localization system and Varian Trilogy on board imaging (OBI) system for setting up phantom and SRS patient. American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting July 18-22, Philadelphia, PA
A Procedure For Standardizing Mlc Quality Assurance For Elekta Linac, K. Yan, M. Studenski, H. Liu, I. Buzurovic, Y. Cui, L. Shabason, A. Harrison, Y. Yu, M. Hossain, Y. Xiao
A Procedure For Standardizing Mlc Quality Assurance For Elekta Linac, K. Yan, M. Studenski, H. Liu, I. Buzurovic, Y. Cui, L. Shabason, A. Harrison, Y. Yu, M. Hossain, Y. Xiao
Hua Kun Liu
Purpose: As specified in TG142, MLC position accuracy needs to be tested on weekly/monthly basis, with 1mm tolerance. This study focuses on developing techniques, hardware and software tools for implementation of MLC QA tests for Elekta Linacs. American Association of Physicists in Medicine (AAPM) 52nd Annual Meeting July 18-22, Philadelphia, PA
Therapeutic Efficacy And Safety Of Paclitaxel/Lonidamine Loaded Egfr-Targeted Nanoparticles For The Treatment Of Multi-Drug Resistant Cancer, Lara S. Jabr-Milane, Zhenfeng Duan, Mansoor M. Amiji
Therapeutic Efficacy And Safety Of Paclitaxel/Lonidamine Loaded Egfr-Targeted Nanoparticles For The Treatment Of Multi-Drug Resistant Cancer, Lara S. Jabr-Milane, Zhenfeng Duan, Mansoor M. Amiji
Mansoor M. Amiji
The treatment of multi-drug resistant (MDR) cancer is a clinical challenge. Many MDR cells over-express epidermal growth factor receptor (EGFR). We exploit this expression through the development of EGFR-targeted, polymer blend nanocarriers for the treatment of MDR cancer using paclitaxel (a common chemotherapeutic agent) and lonidamine (an experimental drug; mitochondrial hexokinase 2 inhibitor). An orthotopic model of MDR human breast cancer was developed in nude mice and used to evaluate the safety and efficacy of nanoparticle treatment. The efficacy parameters included tumor volume measurements from day 0 through 28 days post-treatment, terminal tumor weight measurements, tumor density and morphology assessment …
Multi-Functional Nanocarriers To Overcome Tumor Drug Resistance, Lara S. Jabr-Milane, Lilian E. Van Vlerkin, Sunita Yadav, Mansoor M. Amiji
Multi-Functional Nanocarriers To Overcome Tumor Drug Resistance, Lara S. Jabr-Milane, Lilian E. Van Vlerkin, Sunita Yadav, Mansoor M. Amiji
Mansoor M. Amiji
The development of resistance to variety of chemotherapeutic agents is one of the major challenges in effective cancer treatment. Tumor cells are able to generate a multi-drug resistance (MDR) phenotype due to microenvironmental selection pressures. This review addresses the use of nanotechnology-based delivery systems to overcome MDR in solid tumors. Our own work along with evidence from the literature illustrates the development of various types of engineered nanocarriers specifically designed to enhance tumor-targeted delivery through passive and active targeting strategies. Additionally, multi-functional nanocarriers are developed to enhance drug delivery and overcome MDR by either simultaneous or sequential delivery of resistance …
Issues Related To Sentinel Lymph Node Assessment In The Management Of Breast Cancer—What Are Relevant In Pathology Reports?, Patricia Tai, Kurian J. Joseph, Edward Yu
Issues Related To Sentinel Lymph Node Assessment In The Management Of Breast Cancer—What Are Relevant In Pathology Reports?, Patricia Tai, Kurian J. Joseph, Edward Yu
Edward Yu
Most cancer centers now perform sentinel node (SN) biopsies. The limited number of SNs sampled compared with an axillary dissection has allowed more comprehensive lymph node analysis resulting in increased detection of micrometastases. Many node-negative cases are now reclassified as micrometastatic. Recent research on SN biopsy focuses on whether axillary dissection is always necessary when the SN is positive. Some subgroups of patients have a higher risk of more nodal metastases when completion axillary dissections were performed. This paper summarizes the different studies and examines what are the clinically relevant items to report on SN node pathology: volume or size …